🇺🇸 FDA
Pipeline program

Volrustomig

D798MC00002

Phase 2 mab active

Quick answer

Volrustomig for Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) is a Phase 2 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)
Phase
Phase 2
Modality
mab
Status
active

Clinical trials